|
Video: What is a Stock Split?
|
|
Poseida Therapeutics is a clinical-stage biopharmaceutical company. Co.'s chimeric antigen receptor T cell (CAR-T) product candidate includes P-BCMA-101, which is an autologous CAR-T being developed for the treatment of patients with metastatic castrate resistant prostate cancer. Co.'s dual CAR-T allogeneic program candidates include P-CD19CD20-ALLO1, which is an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications and some autoimmune disease. Co.'s gene therapy programs include P-OTC-101, which is an in vivo liver-directed gene therapy candidate for the treatment of ornithine transcarbamylase deficiency. According to our Poseida Therapeutics stock split history records, Poseida Therapeutics has had 0 splits. | |
|
Poseida Therapeutics (PSTX) has 0 splits in our Poseida Therapeutics stock split history database.
Looking at the Poseida Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Poseida Therapeutics shares, starting with a $10,000 purchase of PSTX, presented on a split-history-adjusted basis factoring in the complete Poseida Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/13/2020 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$13.48 |
|
End price/share: |
$2.13 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-84.20% |
|
Average Annual Total Return: |
-38.55% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,580.16 |
|
Years: |
3.79 |
|
|
|
|
|